Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutations01:39

Mutations

66.9K
Overview
66.9K
Translation01:31

Translation

133.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
133.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Mutations01:35

Mutations

31.4K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
31.4K
Translation01:31

Translation

16.9K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
16.9K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

101
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
101

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bam-readcount - rapid generation of basepair-resolution sequence metrics.

Journal of open source software·2026
Same author

pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design.

ArXiv·2026
Same author

A class of deep intronic <i>IGHMBP2</i> variants activate a shared cryptic splice donor, enabling correction of select variants with a single antisense oligonucleotide.

medRxiv : the preprint server for health sciences·2026
Same author

Optical genome mapping identifies clinically relevant somatic structural variation in epilepsy-affected brain tissue.

medRxiv : the preprint server for health sciences·2026
Same author

Somatic variants activating the RAS-MAPK pathway confer susceptibility to hippocampal sclerosis in drug-resistant epilepsy.

bioRxiv : the preprint server for biology·2026
Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026

Related Experiment Video

Updated: May 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

DNMT3A mutations in acute myeloid leukemia.

Timothy J Ley1, Li Ding, Matthew J Walter

  • 1Department of Genetics, Genome Center, Washington University, St Louis, MO 63110, USA. timley@wustl.edu

The New England Journal of Medicine
|November 12, 2010
PubMed
Summary

Mutations in the DNMT3A gene are common in acute myeloid leukemia (AML) and linked to poor survival, especially in patients with intermediate-risk cytogenetics.

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

7.3K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.5K

Related Experiment Videos

Last Updated: May 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

7.3K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.5K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The genetic basis for adverse outcomes in acute myeloid leukemia (AML) remains largely unknown.
  • Identifying key genetic alterations is crucial for understanding AML progression and patient prognosis.

Purpose of the Study:

  • To investigate the role of DNMT3A mutations in de novo acute myeloid leukemia (AML).
  • To determine the frequency and prognostic significance of DNMT3A mutations in AML patients.

Main Methods:

  • Massively parallel DNA sequencing was employed to identify somatic mutations.
  • The DNMT3A gene's exons were sequenced in 280 de novo AML patients.
  • Genetic alterations were correlated with cytogenetic risk profiles and patient outcomes.

Main Results:

  • DNMT3A mutations were identified in 22.1% of AML patients, with 18 distinct missense mutations and other types of mutations observed.
  • These mutations were significantly enriched in patients with intermediate-risk cytogenetics (33.7%) and absent in those with favorable-risk cytogenetics.
  • Patients with DNMT3A mutations had a significantly shorter median overall survival (12.3 months vs. 41.1 months) and an associated adverse outcome.

Conclusions:

  • DNMT3A mutations are recurrent in de novo AML, particularly in the intermediate-risk cytogenetic group.
  • These mutations are independently associated with a poor prognosis in AML patients.
  • The findings highlight DNMT3A as a significant factor in AML pathogenesis and outcome.